InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
63,061.24
(
0.98%
)
Post# of 253346
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120561
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 216230

Wednesday, 12/27/2017 11:13:18 AM

Wednesday, December 27, 2017 11:13:18 AM

Post# of 253346
Re: Neoantigen vaccines /ADXS-NEO

Curious that the authors of the Nature write-up you posted consider colorectal cancer to be a high-mutation cancer; it is generally thought to be the opposite.

Colorectal cancer will be one of the three indications for the ADXS-NEO neoantigen-vaccine program licensed by AMGN (the other two are NSCLC and H&N: #msg-134949543). According to ADXS’ FY4Q17 CC, the rationale for selecting colorectal cancer is to see if NEO can work in a “cold tumor” setting.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up